XOMA Royalty (NASDAQ:XOMA) Shares Pass Above 200-Day Moving Average – Here’s What Happened

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $31.18 and traded as high as $41.75. XOMA Royalty shares last traded at $41.71, with a volume of 78,306 shares traded.

Analyst Upgrades and Downgrades

XOMA has been the topic of a number of research analyst reports. Lucid Cap Mkts cut shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings lowered shares of XOMA Royalty from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Leerink Partners reissued an “outperform” rating on shares of XOMA Royalty in a research note on Tuesday, February 24th. Benchmark lowered shares of XOMA Royalty from a “buy” rating to a “hold” rating in a research note on Friday, May 22nd. Finally, HC Wainwright cut XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price objective on the stock. in a report on Thursday, April 30th. One equities research analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $53.75.

XOMA Royalty Price Performance

The stock’s fifty day moving average price is $37.88 and its 200-day moving average price is $31.18. The firm has a market cap of $523.04 million, a PE ratio of 26.57 and a beta of 0.90. The company has a debt-to-equity ratio of 0.96, a current ratio of 3.59 and a quick ratio of 3.59.

XOMA Royalty (NASDAQ:XOMA) last posted its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). The business had revenue of $12.32 million for the quarter, compared to analyst estimates of $13.91 million. XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%. As a group, equities analysts expect that XOMA Royalty Corporation will post 0.9 EPS for the current fiscal year.

Hedge Funds Weigh In On XOMA Royalty

A number of institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its stake in XOMA Royalty by 207.7% during the first quarter. Dimensional Fund Advisors LP now owns 133,360 shares of the biotechnology company’s stock worth $4,182,000 after buying an additional 90,025 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of XOMA Royalty by 9.7% in the 1st quarter. Bank of New York Mellon Corp now owns 74,984 shares of the biotechnology company’s stock worth $2,352,000 after acquiring an additional 6,600 shares during the last quarter. Opaleye Management Inc. raised its holdings in shares of XOMA Royalty by 14.7% during the 4th quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock worth $7,780,000 after acquiring an additional 37,503 shares during the period. Squarepoint Ops LLC purchased a new position in shares of XOMA Royalty during the 4th quarter worth $237,000. Finally, Panagora Asset Management Inc. boosted its position in shares of XOMA Royalty by 24.2% during the 4th quarter. Panagora Asset Management Inc. now owns 21,229 shares of the biotechnology company’s stock valued at $564,000 after acquiring an additional 4,135 shares during the last quarter. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.